| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Clinical Research Center, University of Medicine and Dentistry of New Jersey -Robert Wood Johnson Medical School, New Brunswick, NJ 08901; and
Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 10021
The mechanisms of action of marketed TNF-blocking drugs in lesional tissues are still incompletely understood. Because psoriasis plaques are accessible to repeat biopsy, the effect of TNF/lymphotoxin blockade with etanercept (soluble TNFR) was studied in ten psoriasis patients treated for 6 months. Histological response, inflammatory gene expression, and cellular infiltration in psoriasis plaques were evaluated. There was a rapid and complete reduction of IL-1 and IL-8 (immediate/early genes), followed by progressive reductions in many other inflammation-related genes, and finally somewhat slower reductions in infiltrating myeloid cells (CD11c+ cells) and T lymphocytes. The observed decreases in IL-8, IFN-
-inducible protein-10 (CXCL10), and MIP-3
(CCL20) mRNA expression may account for decreased infiltration of neutrophils, T cells, and dendritic cells (DCs), respectively. DCs may be less activated with therapy, as suggested by decreased IL-23 mRNA and inducible NO synthase mRNA and protein. Decreases in T cell-inflammatory gene expression (IFN-, STAT-1, granzyme B) and T cell numbers may be due to a reduction in DC-mediated T cell activation. Thus, etanercept-induced TNF/lymphotoxin blockade may break the potentially self-sustaining cycle of DC activation and maturation, subsequent T cell activation, and cytokine, growth factor, and chemokine production by multiple cell types including lymphocytes, neutrophils, DCs, and keratinocytes. This results in reversal of the epidermal hyperplasia and cutaneous inflammation characteristic of psoriatic plaques.
This article has been cited by other articles:
|
|
 |
|
  H. Wang, T. Syrovets, D. Kess, B. Buchele, H. Hainzl, O. Lunov, J. M. Weiss, K. Scharffetter-Kochanek, and T. Simmet Targeting NF-{kappa}B with a Natural Triterpenoid Alleviates Skin Inflammation in a Mouse Model of Psoriasis J. Immunol., October 1, 2009; 183(7): 4755 - 4763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Haider, M. A. Lowes, M. Suarez-Farinas, L. C. Zaba, I. Cardinale, A. Khatcherian, I. Novitskaya, K. M. Wittkowski, and J. G. Krueger Identification of Cellular Pathways of "Type 1," Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis J. Immunol., February 1, 2008; 180(3): 1913 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Zaba, I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suarez-Farinas, J. Fuentes-Duculan, I. Novitskaya, A. Khatcherian, M. J. Bluth, M. A. Lowes, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses J. Exp. Med., December 24, 2007; 204(13): 3183 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Facco, I. Baesso, M. Miorin, M. Bortoli, A. Cabrelle, E. Boscaro, C. Gurrieri, L. Trentin, R. Zambello, F. Calabrese, et al. Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis J. Leukoc. Biol., October 1, 2007; 82(4): 946 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Iwamoto, S.-i. Iwai, K. Tsujiyama, C. Kurahashi, K. Takeshita, M. Naoe, A. Masunaga, Y. Ogawa, K. Oguchi, and A. Miyazaki TNF-{alpha} Drives Human CD14+ Monocytes to Differentiate into CD70+ Dendritic Cells Evoking Th1 and Th17 Responses J. Immunol., August 1, 2007; 179(3): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Kavanaugh, G G Krueger, A Beutler, C Guzzo, B Zhou, L T Dooley, P J Mease, D D Gladman, K de Vlam, P P Geusens, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial Ann Rheum Dis, April 1, 2007; 66(4): 498 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Chan, W. Blumenschein, E. Murphy, C. Diveu, M. Wiekowski, S. Abbondanzo, L. Lucian, R. Geissler, S. Brodie, A. B. Kimball, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis J. Exp. Med., November 27, 2006; 203(12): 2577 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Melikoglu, S. Uysal, J. G. Krueger, G. Kaplan, F. Gogus, H. Yazici, and S. Oliver Characterization of the Divergent Wound-Healing Responses Occurring in the Pathergy Reaction and Normal Healthy Volunteers J. Immunol., November 1, 2006; 177(9): 6415 - 6421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sutton, C. Brereton, B. Keogh, K. H.G. Mills, and E. C. Lavelle A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis J. Exp. Med., July 10, 2006; 203(7): 1685 - 1691. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
